BioCardia's mission is to bring to market comprehensive cell therapy solutions for the treatment of cardiovascular diseases with large unmet medical needs. BioCardia is a clinical-stage regenerative medicine company. BioCardia lead therapeutic candidate is the investigational CardiAMP™ Cell Therapy System, which provides an autologous bone marrow derived cell therapy (using a patient's own cells) for the treatment of two clinical indications - heart failure that develops after a heart attack and chronic myocardial ischemia. The second therapeutic candidate is the investigational CardiALLO™ Cell Therapy System, an allogeneic culture expanded "off the shelf" cell therapy derived from donor bone marrow cells that have been identified to meet specified criteria. This therapy has the potential to be advanced for many clinical indications including heart failure.
MSCRF helped fund the ongoing CardiAMP Heart Failure trial and lend credibility to our programs at a critical juncture of our efforts.
